Comparing the impact of systemic pituitary adenylate-cyclase-activating polypeptide (PACAP) and calcitonin gene-related peptide (CGRP) on motion-induced nausea and balance behaviors in mice
PLOS One · 2025
DOI: 10.1371/journal.pone.0334444 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift PLOS One, 2025. Verfasst von Shafaqat M Rahman und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, University of Rochester, Rochester, New York, United States of America. Hauptthemen laut MEDLINE: Postural Balance, Motion Sickness, Nausea, Pituitary Adenylate Cyclase-Activating Polypeptide. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute on Deafness and Other Communication Disorders.
Abstract (Originalsprache)
Pituitary adenylate-cyclase-activating polypeptide (PACAP), particularly its dominant isoform PACAP-38, is implicated in migraine and represents a promising therapeutic target. We investigated if intraperitoneally delivered (IP) PACAP-38 impacts motion-induced nausea, postural sway, and imbalance in C57BL/6J wildtype mice using the motion-induced thermoregulation, center of pressure (CoP), rotarod, and balance beam assays. We also assessed systemic Calcitonin Gene-Related Peptide’s (CGRP) effects on these behaviors in parallel. Our findings indicate that IP PACAP-38 significantly disrupts motion-induced thermoregulation in mice, with notable blunting of tail vasodilation responses in both sexes. Additionally, PACAP-38 administration increased postural sway in female mice only and caused balance beam imbalances. Contrary to IP CGRP, IP PACAP-38 did not affect rotarod performance when mice were trained on a dowel with 1.5 cm radius. Our findings provide preclinical evidence supporting a potential role of PACAP-38 in vestibular migraine pathophysiology. Future research will explore if PACAP antagonism can protect against PACAP-38’s effects on nausea and balance behaviors, relevant to treatment of vestibular migraine (VM), especially for patients unresponsive to triptans or CGRP-targeting therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, University of Rochester, Rochester, New York, United States of America.
- Department of Neuroscience, Del Monte Institute of Neuroscience, University of Rochester Medical Center, Rochester, New York, United States of America.
ORCID-Profile: Anne E Luebke
Förderung
- National Institute on Deafness and Other Communication Disorders
Zitieren
APA
Rahman, S. M., Dweh, A., & Luebke, A. E. (2025). Comparing the impact of systemic pituitary adenylate-cyclase-activating polypeptide (PACAP) and calcitonin gene-related peptide (CGRP) on motion-induced nausea and balance behaviors in mice. PLOS One. https://doi.org/10.1371/journal.pone.0334444
Vancouver
Rahman SM, Dweh A, Luebke AE. Comparing the impact of systemic pituitary adenylate-cyclase-activating polypeptide (PACAP) and calcitonin gene-related peptide (CGRP) on motion-induced nausea and balance behaviors in mice. PLOS One. 2025. doi:10.1371/journal.pone.0334444
BibTeX
@article{Rahman2025,
author = {Rahman, Shafaqat M and Dweh, Abigail and Luebke, Anne E},
title = {Comparing the impact of systemic pituitary adenylate-cyclase-activating polypeptide (PACAP) and calcitonin gene-related peptide (CGRP) on motion-induced nausea and balance behaviors in mice},
journal = {PLOS One},
year = {2025},
doi = {10.1371/journal.pone.0334444}
}
EUVIMED